JP4120586B2 - ２−アシルアミノチアゾール誘導体又はその塩 - Google Patents

２−アシルアミノチアゾール誘導体又はその塩 Download PDF

Info

Publication number
JP4120586B2
JP4120586B2 JP2003562111A JP2003562111A JP4120586B2 JP 4120586 B2 JP4120586 B2 JP 4120586B2 JP 2003562111 A JP2003562111 A JP 2003562111A JP 2003562111 A JP2003562111 A JP 2003562111A JP 4120586 B2 JP4120586 B2 JP 4120586B2
Authority
JP
Japan
Prior art keywords
thiazol
added
chlorothiophen
cyclohexylpiperazin
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003562111A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2003062233A1 (ja
Inventor
形造 菅沢
晋 四月朔日
祐司 古賀
宏 長田
和義 小櫃
竜太郎 若山
復志 平山
健一 鈴木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of JPWO2003062233A1 publication Critical patent/JPWO2003062233A1/ja
Application granted granted Critical
Publication of JP4120586B2 publication Critical patent/JP4120586B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2003562111A 2002-01-18 2003-01-15 ２−アシルアミノチアゾール誘導体又はその塩 Expired - Lifetime JP4120586B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002010413 2002-01-18
JP2002010447 2002-01-18
JP2002010447 2002-01-18
JP2002010413 2002-01-18
PCT/JP2003/000270 WO2003062233A1 (en) 2002-01-18 2003-01-15 2-acylaminothiazole derivative or salt thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008023950A Division JP4844574B2 (ja) 2002-01-18 2008-02-04 ２−アシルアミノチアゾール誘導体又はその塩

Publications (2)

Publication Number Publication Date
JPWO2003062233A1 JPWO2003062233A1 (ja) 2005-05-19
JP4120586B2 true JP4120586B2 (ja) 2008-07-16

Family

ID=27615666

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003562111A Expired - Lifetime JP4120586B2 (ja) 2002-01-18 2003-01-15 ２−アシルアミノチアゾール誘導体又はその塩
JP2008023950A Expired - Lifetime JP4844574B2 (ja) 2002-01-18 2008-02-04 ２−アシルアミノチアゾール誘導体又はその塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008023950A Expired - Lifetime JP4844574B2 (ja) 2002-01-18 2008-02-04 ２−アシルアミノチアゾール誘導体又はその塩

Country Status (17)

Country Link
US (4) US7638536B2 (OSRAM)
EP (2) EP2314586B1 (OSRAM)
JP (2) JP4120586B2 (OSRAM)
KR (1) KR101010905B1 (OSRAM)
CN (1) CN1319967C (OSRAM)
BE (1) BE2019C547I2 (OSRAM)
CA (1) CA2472711C (OSRAM)
CY (2) CY1114169T1 (OSRAM)
DK (1) DK1466912T3 (OSRAM)
ES (2) ES2416304T3 (OSRAM)
FR (1) FR19C1072I2 (OSRAM)
HU (1) HUS1900052I1 (OSRAM)
LU (1) LUC00137I2 (OSRAM)
NL (1) NL301020I2 (OSRAM)
PT (1) PT1466912E (OSRAM)
SI (1) SI1466912T1 (OSRAM)
WO (1) WO2003062233A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008111001A (ja) * 2002-01-18 2008-05-15 Astellas Pharma Inc ２−アシルアミノチアゾール誘導体又はその塩

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
AU2003212335B8 (en) * 2002-03-13 2009-04-23 Janssen Pharmaceutica N.V. Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
AU2003268687A1 (en) * 2002-09-30 2004-04-19 Yamanouchi Pharmaceutical Co., Ltd. Novel salt of 2-acylaminothiazole derivative
MXPA06000441A (es) * 2003-07-17 2006-04-05 Astellas Pharma Inc Derivado de 2-acilaminotiazole o sal del mismo.
EP1655291B1 (en) * 2003-08-12 2016-08-03 Shionogi & Co., Ltd. Compounds having thrombopoietin receptor agonism
BRPI0418082B8 (pt) 2003-12-26 2021-05-25 Kyowa Hakko Kirin Co Ltd derivados de tiazol úteis como antagonistas de receptor de adenosina a2a
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
ATE537830T1 (de) * 2004-07-06 2012-01-15 Xenon Pharmaceuticals Inc Nicotinamid derivate und ihre verwendung als therapeutika
BRPI0515499A (pt) * 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de piridina para a inibição de estearoil-coa-desaturase humana
NZ554662A (en) * 2004-10-25 2008-11-28 Ligand Pharm Inc Thrombopoietin activity modulating compounds and methods
US8552031B2 (en) 2004-12-08 2013-10-08 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
WO2006064957A1 (ja) 2004-12-14 2006-06-22 Nissan Chemical Industries, Ltd. アミド化合物及びトロンボポエチンレセプター活性化剤
JP4665769B2 (ja) * 2005-01-12 2011-04-06 アステラス製薬株式会社 アシルアミノチアゾール誘導体の製造法
JP4774995B2 (ja) * 2005-01-12 2011-09-21 アステラス製薬株式会社 アシルアミノチアゾール誘導体を有効成分とする医薬組成物
US20100280023A1 (en) * 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
WO2007036769A1 (en) * 2005-07-05 2007-04-05 Pfizer Products Inc. Aminothiazole derivatives as agonists of the thrombopoietin receptor
WO2007004038A1 (en) * 2005-07-05 2007-01-11 Pfizer Products Inc. Aminothiazole derivatives as agonists of the thrombopoietin receptor
CA2614726A1 (en) * 2005-07-13 2007-01-18 Astrazeneca Ab New pyridine analogues
CA2609319C (en) 2005-07-15 2014-02-04 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
TWI330184B (en) 2005-07-20 2010-09-11 Nissan Chemical Ind Ltd Pyrazole compounds and thrombopoietin receptor activators
KR101350099B1 (ko) 2005-11-07 2014-01-09 닛산 가가쿠 고교 가부시키 가이샤 하이드라지드 화합물 및 트롬보포이에틴 리셉터 활성화제
EP1971368A4 (en) * 2005-11-08 2009-08-05 Astellas Pharma Inc COMPOSITIONS AND METHODS FOR TREATING THROMBOCYTOPENIA
EP2025671A4 (en) * 2006-06-07 2011-04-06 Nissan Chemical Ind Ltd NITROGENIC HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
JP2010500361A (ja) * 2006-08-08 2010-01-07 アカークス，インコーポレーテッド ヒトの血小板レベルを増加させるための組成物および方法
JP5164510B2 (ja) * 2006-10-06 2013-03-21 日本曹達株式会社 含窒素複素環化合物および有害生物防除剤
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
AU2008283357B2 (en) 2007-07-31 2011-08-11 Shionogi & Co., Ltd. Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity and intermediate thereof
ES2331220B1 (es) * 2007-10-02 2010-09-23 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
WO2009048953A1 (en) * 2007-10-09 2009-04-16 The Trustees Of The University Of Pennsylvania Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells
MX2010009082A (es) * 2008-02-25 2010-09-07 Merck Patent Gmbh Activadores de glucocinasa.
US8476249B2 (en) 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
US8680150B2 (en) * 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
JP2013501811A (ja) * 2009-08-14 2013-01-17 エーザイ インコーポレーテッド 血小板産生を刺激するためのｅ５５０１の使用
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JP2014144916A (ja) 2011-08-03 2014-08-14 Astellas Pharma Inc ２−アシルアミノチアゾール化合物の結晶
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
AU2012337781B2 (en) 2011-11-15 2017-07-06 Takeda Pharmaceutical Company Limited Dihydroxy aromatic heterocyclic compound
EP2832731A4 (en) * 2012-03-27 2015-08-19 Shionogi & Co AROMATIC HETEROCYCLIC CHAIN 5-CORE DERIVED DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
TWI647227B (zh) * 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 ２－醯胺噻唑衍生物或其鹽
SG11201504704TA (en) 2013-03-14 2015-07-30 Dart Neuroscience Llc Substituted naphthyridine and quinoline compounds as mao inhibitors
CN105492444B (zh) 2013-07-02 2018-09-07 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
JP6522602B2 (ja) 2013-07-02 2019-05-29 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
DK3153511T3 (da) 2014-06-06 2019-06-24 Astellas Pharma Inc 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme
US9844549B2 (en) 2014-08-26 2017-12-19 Astellas Pharma Inc. 2-aminothiazole derivative or salt thereof
JP6658535B2 (ja) 2014-10-31 2020-03-04 日産化学株式会社 リガンド結合繊維及び当該繊維を用いた細胞培養基材
US20190315771A1 (en) * 2016-09-08 2019-10-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Novel 2-acylaminothiazole derivative and preparation method therefor and use thereof
CN106749226B (zh) * 2017-03-15 2019-12-20 广东赛拓医药科技有限公司 一种avatrombopag马来酸盐晶型C的制备方法
CN107383000A (zh) * 2017-08-07 2017-11-24 瑞阳制药有限公司 血小板增多剂的制备方法
WO2020044364A1 (en) 2018-08-27 2020-03-05 Mylan Laboratories Limited Polymorphic forms of avatrombopag maleate
RU2709496C1 (ru) * 2019-08-01 2019-12-18 Марат Феликсович Фазылов Способ получения аватромбопага
CN110586047B (zh) * 2019-10-08 2022-03-11 辽宁工业大学 一种用于吸附铅离子的改性双醛淀粉制备方法
CN111620863A (zh) * 2020-06-23 2020-09-04 苏州明锐医药科技有限公司 阿曲波帕的制备方法
CN115057854A (zh) * 2022-04-19 2022-09-16 河北常山生化药业股份有限公司 马来酸阿伐曲泊帕中间体的制备方法
CN115477645A (zh) * 2022-09-28 2022-12-16 湖南先施制药有限公司 马来酸阿伐曲泊帕系列杂质及其制备方法和应用
CN116813609A (zh) * 2023-07-03 2023-09-29 上海天鹤年药业有限公司 一种阿伐曲泊帕的制备方法
WO2025132929A2 (en) 2023-12-19 2025-06-26 Synthon B.V Salts of avatrombopag
WO2025133011A1 (en) 2023-12-21 2025-06-26 Synthon B.V Formulation comprising form b of avatrombopag maleate
EP4660195A1 (en) 2024-06-05 2025-12-10 Noucor Health S.A. Crystalline forms of avatrombopag maleate and preparation thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330998A (en) 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5256675A (en) * 1989-08-07 1993-10-26 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same
TW205041B (OSRAM) 1989-08-07 1993-05-01 Fujisawa Pharmaceutical Co
JPH078863B2 (ja) 1989-09-21 1995-02-01 久光製薬株式会社 新規なジフェニルチアゾール誘導体
IE68593B1 (en) 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
JPH03199451A (ja) 1989-12-26 1991-08-30 Asahi Chem Ind Co Ltd エアージェットルーム用筬
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
JP3173876B2 (ja) 1992-06-26 2001-06-04 日本パイオニクス株式会社 有害ガスの検知システム
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
EP0747355A4 (en) 1994-02-10 1997-04-09 Yamanouchi Pharma Co Ltd NEW CARBAMATES AND MEDICINAL PRODUCTS CONTAINING THEM
AU4889496A (en) * 1995-03-09 1996-10-02 Kyowa Hakko Kogyo Co. Ltd. Pyrrolocarbazole derivatives
KR19990008109A (ko) * 1995-04-28 1999-01-25 나가사까 겐지로 1,4-이치환 피페리딘 유도체
EA001220B1 (ru) * 1995-06-07 2000-12-25 Глаксо Груп Лимитед Пептид или пептидомиметик, который связывается с рецептором тромбоэтина, фармацевтическая композиция и способ лечения
US5963666A (en) * 1995-08-18 1999-10-05 International Business Machines Corporation Confusion matrix mediated word prediction
DE69626624T2 (de) * 1995-10-17 2003-11-27 Daiichi Suntory Pharma Co., Ltd. Medikamente gegen trhombocytopenie
DE69724438T2 (de) 1996-05-22 2004-06-09 Smithkline Beecham Corp. Nicht peptidische g-csf mimetika
AU4136197A (en) 1996-09-09 1998-03-26 Kyowa Hakko Kogyo Co. Ltd. Pyrrolocarbazole derivatives
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
JPH10212289A (ja) 1997-01-31 1998-08-11 Kyowa Hakko Kogyo Co Ltd ピロロフェナンスリジン誘導体
AU9265698A (en) 1997-09-02 1999-03-22 Boehringer Mannheim Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing themand their use for the treatment and prevention of thrombocytopaenia and anaemia
JPH11152276A (ja) 1997-11-20 1999-06-08 Hokuriku Seiyaku Co Ltd ベンゾジアゼピン誘導体
JP2000044562A (ja) 1998-07-31 2000-02-15 Kyowa Hakko Kogyo Co Ltd ピロロフタルイミド誘導体
CA2337755C (en) 1998-09-18 2008-07-29 Vertex Pharmaceuticals Incorporated Inhibitors of p38
WO2000028987A1 (en) * 1998-11-17 2000-05-25 Smithkline Beecham Corporation Methods of treating thrombocytopenia
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
CN1376150A (zh) 1999-07-26 2002-10-23 盐野义制药株式会社 具有血栓形成素受体拮抗作用的药物组合物
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
WO2002049632A1 (en) 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
WO2002053160A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ivb
EP1364949A4 (en) 2001-02-02 2005-11-23 Takeda Pharmaceutical JNK INHIBITOR
JPWO2002062775A1 (ja) * 2001-02-02 2004-06-10 山之内製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
US7638536B2 (en) * 2002-01-18 2009-12-29 Astellas Pharma Inc. 2-Acylaminothiazole derivative or salt thereof
WO2003075921A2 (en) 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
US6900219B2 (en) 2002-04-04 2005-05-31 Cv Therapeutics, Inc. ABCA-1 elevating compounds
CN100490793C (zh) 2002-06-11 2009-05-27 株式会社医药分子设计研究所 神经变性疾病治疗药
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
AU2003268687A1 (en) 2002-09-30 2004-04-19 Yamanouchi Pharmaceutical Co., Ltd. Novel salt of 2-acylaminothiazole derivative
EP1594847A2 (en) 2003-02-12 2005-11-16 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
US20040235834A1 (en) * 2003-03-25 2004-11-25 Farmer Luc J. Thiazoles useful as inhibitors of protein kinases
MXPA06000441A (es) 2003-07-17 2006-04-05 Astellas Pharma Inc Derivado de 2-acilaminotiazole o sal del mismo.
EP1655291B1 (en) 2003-08-12 2016-08-03 Shionogi & Co., Ltd. Compounds having thrombopoietin receptor agonism
EP1971368A4 (en) 2005-11-08 2009-08-05 Astellas Pharma Inc COMPOSITIONS AND METHODS FOR TREATING THROMBOCYTOPENIA
JP2010500361A (ja) 2006-08-08 2010-01-07 アカークス，インコーポレーテッド ヒトの血小板レベルを増加させるための組成物および方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008111001A (ja) * 2002-01-18 2008-05-15 Astellas Pharma Inc ２−アシルアミノチアゾール誘導体又はその塩

Also Published As

Publication number Publication date
CN1639157A (zh) 2005-07-13
DK1466912T3 (da) 2013-07-01
US8765764B2 (en) 2014-07-01
US20100222329A1 (en) 2010-09-02
US7638536B2 (en) 2009-12-29
CY1114169T1 (el) 2016-08-31
EP1466912A4 (en) 2006-01-11
JPWO2003062233A1 (ja) 2005-05-19
CN1319967C (zh) 2007-06-06
CA2472711A1 (en) 2003-07-31
HUS1900052I1 (hu) 2020-01-28
NL301020I2 (nl) 2020-04-21
CY2019045I1 (el) 2020-05-29
BE2019C547I2 (OSRAM) 2022-05-17
JP2008111001A (ja) 2008-05-15
KR101010905B1 (ko) 2011-01-25
US20130079351A1 (en) 2013-03-28
KR20040078122A (ko) 2004-09-08
NL301020I1 (OSRAM) 2019-12-16
US20100222361A1 (en) 2010-09-02
CY2019045I2 (el) 2020-05-29
FR19C1072I1 (fr) 2020-01-17
US8338429B2 (en) 2012-12-25
PT1466912E (pt) 2013-06-28
ES2610611T3 (es) 2017-04-28
CA2472711C (en) 2012-03-20
JP4844574B2 (ja) 2011-12-28
EP1466912A1 (en) 2004-10-13
EP2314586B1 (en) 2016-09-14
LUC00137I1 (OSRAM) 2019-11-14
EP1466912B1 (en) 2013-04-24
FR19C1072I2 (fr) 2021-03-26
US20050153977A1 (en) 2005-07-14
ES2416304T3 (es) 2013-07-31
WO2003062233A1 (en) 2003-07-31
LUC00137I2 (OSRAM) 2020-06-12
SI1466912T1 (sl) 2013-08-30
EP2314586A1 (en) 2011-04-27

Similar Documents

Publication Publication Date Title
JP4120586B2 (ja) ２−アシルアミノチアゾール誘導体又はその塩
TWI461423B (zh) 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
JP4324791B2 (ja) ２−アシルアミノチアゾール誘導体又はその塩
JP4966866B2 (ja) ｍＧｌｕＲ５アンタゴニストとしてのチアゾール−４−カルボキサミド誘導体
JPWO2002062775A1 (ja) ２−アシルアミノチアゾール誘導体又はその塩
ES2375586T3 (es) Derivados de imidazolidinona.
SK14952001A3 (sk) 5-Pyridyl-1,3-azolové zlúčeniny, spôsob výroby a použitia
WO1999019303A1 (en) Pyrazole derivatives
WO2002046186A1 (en) Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
KR20170013987A (ko) 2-아실아미노티아졸 유도체 또는 그의 염
CN103080086B (zh) 抑制前列腺素d合成酶的哌啶化合物
JP4774995B2 (ja) アシルアミノチアゾール誘導体を有効成分とする医薬組成物
CN100491355C (zh) 带有五元环基团的环状二胺化合物
JP2001114690A (ja) ｐ３８ＭＡＰキナーゼ阻害剤
KR20100022080A (ko) 뇌경색 치료제
CN106573928A (zh) 2‑氨基噻唑衍生物或其盐
HK1157336A (en) 2-acylaminothiazole derivative or salt thereof
HK1157336B (en) 2-acylaminothiazole derivative or salt thereof
JPWO2002006237A1 (ja) ジシアノピリジン誘導体からなる医薬

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080204

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20080204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080414

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110509

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4120586

Country of ref document: JP

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110509

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120509

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120509

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130509

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130509

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140509

Year of fee payment: 6

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140509

Year of fee payment: 6

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term